<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164778">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01854697</url>
  </required_header>
  <id_info>
    <org_study_id>M13-774</org_study_id>
    <secondary_id>2012-003754-84</secondary_id>
    <nct_id>NCT01854697</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before</brief_title>
  <acronym>MALACHITE 1</acronym>
  <official_title>A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of three experimental drugs compared
      with Telaprevir (a licensed product) in people with hepatitis C virus infection who have not
      had treatment before.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to demonstrate that treatment with ABT-450/r/ABT-267
      and ABT-333 administered with or without Ribavirin (RBV) has non-inferior efficacy compared
      to treatment with telaprevir and pegylated interferon a-2a (pegIFN) and RBV and to compare
      the safety of these regimens in treatment-naive HCV genotype (GT) 1a- and 1b-infected
      adults.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The percentage of all dosed subjects with sustained virologic response following the last actual dose of study drug.</measure>
    <time_frame>12 weeks after the last actual dose of active study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in general health-related quality of life using the Short-Form 36 Version 2 health status survey (SF-36V2) Mental Component Summary (MCS)</measure>
    <time_frame>From Day 1 of treatment up to 12 weeks for arms A,C and D and up to 24 or 48 weeks for arms B and E</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change in the MCS from baseline to final treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in general health-related quality of life using the SF-36V2 Physical Component Summary (PCS) scores</measure>
    <time_frame>From Day 1 of study up to week 12 for arms A,C and D and week 24 or week 48 for arms B and E</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change in the PCS from baseline to final treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</measure>
    <time_frame>12 weeks after the last actual dose of active study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with virologic failures during treatment</measure>
    <time_frame>12 weeks for Arms A, C and D and 24 weeks or 48 weeks for arms B and E</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects in Arms A, C and D demonstrating any of the following will be discontinued from therapy:
Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements of &gt;1 log10 IU/mL above nadir) at any time point during treatment
Failure to achieve HCV RNA &lt; LLOQ by Week 6 or
Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point after HCV RNA &lt; LLOQ during treatment after HCV RNA &lt; LLOQ.
Subjects in Arms B and E will follow the virologic stopping criteria described in the telaprevir Summary of Product Characteristics (SmPC). Subjects in Arm B will discontinue therapy as follows:
HCV RNA &gt; 1000 IU/mL at Week 4 to Week 12, discontinue telaprevir and pegIFN and RBV
HCV RNA &gt; 1000 IU/mL at Week 12, discontinue pegIFN and RBV
Confirmed HCV RNA &gt; Lower Limit of Detection (LLOD) at Week 24, discontinue pegIFN and RBV d.
Confirmed HCV RNA &gt; LLOD at Week 36, discontinue pegIFN and RBV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with post-treatment relapse</measure>
    <time_frame>Within 48 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (LLOQ) between the end of treatment and 48 weeks post treatment among subjects completing treatment and with HCV RNA less than the LLOQ at the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 Direct-Acting Antivirals (DAAs) with RBV in GT1a)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alpha 2-alpha (PegIFN)</intervention_name>
    <description>Pre-filled syringe</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 18 and 65 years, inclusive, at time of Screening.

          -  Females must be post-menopausal for more than 2 years or surgically sterile or
             practicing abstinence/specific forms of birth control

          -  Subject has never received antiviral treatment for hepatitis C infection.

          -  Chronic HCV Genotype-1 infection prior to study enrollment.

        Exclusion Criteria:

          -  Recent (within 6 months prior to study drug administration) history of drug or
             alcohol abuse that could preclude adherence to the protocol.

          -  Positive screen for drugs or alcohol.

          -  Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human
             Immunodeficiency virus antibody (HIV Ab).

          -  Females who are pregnant or plan to become pregnant, or breastfeeding

          -  Any current or past clinical evidence of cirrhosis

          -  Screening laboratory analyses that showing abnormal laboratory results

          -  Use of contraindicated medications within 2 weeks of dosing and subject with
             contraindication for Telaprevir, PegIFN and RBV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan   Luo, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94275</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94428</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94429</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AWK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95212</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JJS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96544</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96545</name>
      <address>
        <city>Brisbane</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96547</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96546</name>
      <address>
        <city>Darlinghurst, Sydney</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96539</name>
      <address>
        <city>Fitzroy Victoria</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96548</name>
      <address>
        <city>Fremantle</city>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96543</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96462</name>
      <address>
        <city>Hamilton</city>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96459</name>
      <address>
        <city>Montreal</city>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96458</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96463</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96461</name>
      <address>
        <city>Vaughan</city>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96460</name>
      <address>
        <city>Victoria</city>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94459</name>
      <address>
        <city>Renaca, Vina del Mar</city>
        <zip>25403-64</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94458</name>
      <address>
        <city>Santiago</city>
        <zip>7650568</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94460</name>
      <address>
        <city>Santiago</city>
        <zip>833-0024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 111075</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96315</name>
      <address>
        <city>Turku</city>
        <zip>21200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94075</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94074</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94073</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94076</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94077</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98315</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95678</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1603</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95676</name>
      <address>
        <city>Lorenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95677</name>
      <address>
        <city>Tromso</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94134</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94139</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94140</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94078</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94093</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94094</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94096</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96035</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96036</name>
      <address>
        <city>Iasi</city>
        <zip>700116</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94098</name>
      <address>
        <city>Timisoara</city>
        <zip>300167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94158</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94157</name>
      <address>
        <city>Bratislava</city>
        <zip>811 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94156</name>
      <address>
        <city>Bratislava</city>
        <zip>831 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Interferon Free</keyword>
  <keyword>Hepatitis C Treatment Naive</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon Alfa-2a</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
